If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
75
results.
Updated on
21/02/2026 [07:36:00]
Results 50 to 75 of 75
Absstract of: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Absstract of: WO2026009791A1
Provided is a detection sensitivity-improving method for improving the sensitivity of detection of a protein. The detection sensitivity-improving method, which is used in a method for detecting, by an antigen-antibody reaction, a protein supported by a matrix, includes performing, before the antigen-antibody reaction, a boiling treatment in which the matrix on which the protein is supported is boiled in a sodium sulfate solution to thereby improve the sensitivity of detection of the protein by the antigen-antibody reaction. The protein is an etiological protein of dementia, such as Aβ and Tau. The method can also be applied to the improvement of the sensitivity of detection of a tag protein such as a His tag, an myc tag and a FLAG tag.
Absstract of: US20260009787A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease and hypoplastic left heart syndrome (HLHS) with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers.
Absstract of: US20260007714A1
The present disclosure provides methods of reducing the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury (DILI). The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
Absstract of: US20260009082A1
Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's disease, cardiovascular disease, arthritis, and adverse pregnancy outcomes. The devices, kits, and methods utilize an analysis of single nucleotide polymorphisms (SNPs) from various interleukins.
Absstract of: US20260008840A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Absstract of: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Absstract of: EP4675277A1
The present invention relates to a method for diagnosing or determining the risk of suffering from Alzheimer's disease in a subject, wherein the method comprises determining the level of at least the biomarkers Neurofilament light Chain (NfL), brain-derived neurotrophic factor (BDNF), and tumor growth factor beta 1 (TGF-beta 1) and in addition determining the level of one or more biomarkers selected from the group comprising interleukin 18 (IL-18), Monocyte chemotactic protein-1 (MCP-1), Insulin-like growth factor (IGF) and Vascular endothelial growth factor (VEGF) in a sample of bodily fluid of said subject, calculating a score from the determined biomarker levels, and comparing said score with a reference score, and wherein said subject is diagnosed with Alzheimer's disease, or said subject is determined as having a risk of suffering from Alzheimer's disease, if the score is above said reference score.
Absstract of: MX2025010930A
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Absstract of: US2021132085A1
The present disclosure relates to identifying an individual as having or being at risk of developing an amyloid-positive dementia based on marker molecules amyloid β40 (Aβ40), amyloid β42 (Aβ42) and total Tau (tTau), the use of the marker molecules for the identification of an individual having or being at risk of developing an amyloid-positive dementia and a method for detecting an individual with an increased value for the combination of the marker molecules.
Absstract of: US2025189536A1
The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.
Absstract of: WO2026006441A1
Some embodiments provide for a method for performing a multi-biomarker beta¬ amyloid status determining assay. The method may include: obtaining, for one or more blood or blood-derived samples, values for biomarkers associated with Alzheimer's disease, the values comprising a value for a phosphorylated Tau (p-Tau) and one or more values for one or more additional biomarkers; comparing the value for p-Tau to upper and lower thresholds to determine whether the value for p-Tau is greater than or equal to the lower threshold and less than or equal to the upper threshold; and after determining that the value for p-Tau is greater than or equal to the lower threshold and less than or equal to the upper threshold, further interrogating the intermediate range values that are indicative of borderline cases of amyloid pathology using a statistical model to obtain an output facilitating additional classification of the likelihood that the one or more blood or blood-derived samples are associated with a particular beta-amyloid status.
Absstract of: WO2026005695A1
The invention relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to human tau. The monoclonal antibody, or the antigen-binding fragment thereof, can be used in a homogenous immunoassay for the detection and quantification of oligomeric tau and soluble tau aggregates in body fluid samples.
Absstract of: WO2024243435A2
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Absstract of: US20260002934A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Absstract of: EP4671765A1
The present disclosure discloses a method, system, composition, and kit for diagnosis and differential diagnosis of Alzheimer's disease (AD) based on spatial transcriptomics of a human hippocampus. In the present disclosure, the rapid and efficient early diagnosis and differential diagnosis of AD-associated cognitive impairment is achieved based on one or more of cholecystokinin (CCK), neurogranin (NRGN), and peripheral myelin protein 2 (PMP2) that are carried by plasma extracellular vesicles (EVs). The present disclosure enables the high-sensitivity and high-throughput detection of nervous system-derived EVs in peripheral blood, and demonstrates advantages such as high efficiency and low cost. The present disclosure provides a new technical means and method for the clinical application and large-scale screening related to the accurate diagnosis of AD-associated cognitive impairment.
Absstract of: EP4671757A2
Provided herein is the use of a compound of Formula I:or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Absstract of: WO2025265006A2
The present invention relates to kits and diagnostic methods for multiple biomarkers or their isoforms as well as to methods for determining and selecting treatment methods based on the results obtained from said kits and diagnostic methods. In particular, the invention relates to improved lateral flow (LFA) strips, cassettes containing the LFA assay strips as well as to kits containing the strips and cassettes. The invention also relates to methods for subclassing patients into various subtypes based on the simultaneous detection of three or more different biomarkers or isoforms of biomarkers.
Absstract of: US2025389734A1
A method for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases, comprising determining the level of TPK1 protein in a sample from a subject, wherein a decrease in the level of TPK1 protein compared to a reference value indicates that the subject has Alzheimer's disease. Methods, compositions, test strips, test cards and/or kits for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases by detecting a biomarker, wherein the methods, compositions, test strips, test cards and/or kits can specifically diagnose Alzheimer's disease.
Absstract of: US2025389733A1
The current disclosure describes a method to differentiate whether a blood sample belongs to a normal group or a risk group considering isoAsp. The disclosed method comprises: obtaining a first set of test blood samples and a second set of blood samples that are considered belonging to a normal (control) group; obtaining plasma from said blood samples; measuring the relative abundance of anti-isoaspartate antibodies in each plasma sample; measuring the occupancy of isoaspartate residue in a representative HSA sequence location in each plasma sample; based on the distributions in the set of normal plasma samples of the relative abundances of anti-isoaspartate antibodies and of the occupancies of isoaspartate residues in a representative HSA sequence location, establishing a statistical model for the probability for a given plasma sample to be a normal sample; attributing every plasma test sample to either normal or risk group based on the maximum likelihood according to their measured values and said statistical model.
Absstract of: US2025389714A1
The present invention provides pharmaceutical composition for the treatment of tauopathy-related diseases that can significantly improve cognitive and behavioral impairments by reducing neuronal uptake and propagation of disease-associated tau.
Absstract of: US2025388967A1
The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.
Absstract of: EP4667941A1
The present disclosure relates to a composition for diagnosing cognitive dysfunction in a companion animal using a nasal fluid sample, and to a kit including the same.
Absstract of: CN120329431A
The present invention provides a method of measuring the amount of mono-or poly-phosphorylated p217 + tau protein in a sample. Also provided are methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of treatment of tauopathies, and methods of determining whether a subject is suitable for anti-p217 + tau antibody therapy. Antibodies for use in the methods and kits comprising the antibodies are also described.
Nº publicación: JP2025541672A 23/12/2025
Applicant:
グリフォンバイオ，インク．
Absstract of: CN120660001A
A method of determining the extent of a central nervous system (CNS)-specific neurological disease in a subject includes collecting a sample of a biological fluid of the subject and measuring the amount of a first biomarker or a metabolite thereof or a corresponding mRNA in the sample by a dry spot or microfluidic device. The body fluid is blood capillary blood or saliva, and is suitable for on-site, hospital and family environments due to the advantage of convenient collection. The method has general practicability in the aspects of diagnosis, nursing and management of brain specific abnormal nerve diseases, and is particularly suitable for traumatic brain injury (TBI), Alzheimer's disease (AD) (induced by TBI) and Alexander disease (a disease of white matter deterioration caused by GFAP mutation).
BOPI
Electronic site
